Global pharma major Lupin Limited (Lupin) in partnership with Pharmascience Inc. today announced that it has received tentative approval from the United States Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA), Dasatinib Tablets, 20 mg, 50 mg, 70 mg, 80 mg, 100 mg, and 140 mg, to market a generic equivalent of Sprycel® Tablets, 20 mg, 50 mg, 70 mg, 80 mg, 100 mg, and 140 mg, of Bristol-Myers Squibb Company.
Dasatinib Tablets (RLD Sprycel®) had estimated annual sales of USD 1569 million in the U.S. (IQVIA MAT June 2022).
Shares of Lupin Limited was last trading in BSE at Rs. 652.80 as compared to the previous close of Rs. 665.00. The total number of shares traded during the day was 78994 in over 4308 trades.
The stock hit an intraday high of Rs. 672.95 and intraday low of 651.20. The net turnover during the day was Rs. 52043945.00.